Agilisium has announced a significant investment of Rs 50 crore aimed at revolutionising the life sciences sector by facilitating the operationalisation of artificial intelligence (AI) within pharmaceutical, biotech, and medical technology companies.
Investment Highlights
- Agilisium’s investment focuses on transforming enterprises in the pharmaceutical, biotech, and medical technology domains through the integration of AI.
- The initiative introduces Forward Deployment Experts (FDX), a new professional standard encompassing four critical areas: domain expertise, AI, technology, and consultative solutions.
- The company is committed to reskilling and deploying its global workforce, comprising over 1,000 professionals, as embedded AI transformation partners.
- The forward-deployment model uniquely combines life sciences domain knowledge with AI engineering and data science capabilities.
- Agilisium aims to embed AI capabilities within life sciences organisations to foster future leadership in the sector.
According to a statement from the city-based company issued on Wednesday, Agilisium’s investment is strategically designed to enable pharmaceutical, biotech, and medical technology enterprises to fully operationalise AI, thereby enhancing their business processes.
Through the introduction of Forward Deployment Experts (FDX), Agilisium is establishing a new professional standard that encompasses domain expertise, AI applications, technology integration, consultative solutions, and process thinking.
In a departure from traditional consulting models, Agilisium’s forward-deployment approach integrates deep life sciences domain expertise with AI engineering and data science capabilities. This innovative model positions Agilisium professionals alongside scientists, clinical teams, and commercial stakeholders to design, deploy, and continuously operate AI-driven capabilities.
Agilisium’s Perspective on AI Adoption
In addressing the significance of this initiative, Agilisium’s Founder and CEO, Raj Babu, remarked that the primary constraint to AI adoption in life sciences is no longer technological; rather, it is the availability of skilled talent. He asserted that the companies poised to lead in the life sciences sector over the next decade will not merely be those that acquire AI models, but those that embed AI capabilities deeply within their organisations.
Babu further emphasised that Agilisium’s competitive advantage lies in the extensive institutional and domain knowledge cultivated through its exclusive focus on the life sciences sector.
This investment by Agilisium represents a forward-thinking approach to harnessing the potential of AI in the life sciences domain, aligning with the broader goals of responsible research and innovation.
For those interested in exploring funding opportunities in AI and life sciences, please refer to relevant resources and initiatives that support innovation in this critical area.
Disclaimer: News content is sourced from the stated source. Headlines, summaries, section headers, and images are automatically generated or selected using AI/algorithms and may not always be fully accurate. Readers are advised to refer to the full article for complete context.